Pacific Heights Asset Management Has Lowered Its Nucor (NUE) Holding; Aptose Biosciences (APTO) Shorts Decreased By 17.46%

February 19, 2018 - By Adrian Mccoy

Aptose Biosciences Incorporated (NASDAQ:APTO) had a decrease of 17.46% in short interest. APTO’s SI was 488,400 shares in February as released by FINRA. Its down 17.46% from 591,700 shares previously. With 290,300 avg volume, 2 days are for Aptose Biosciences Incorporated (NASDAQ:APTO)’s short sellers to cover APTO’s short positions. The SI to Aptose Biosciences Incorporated’s float is 3.1%. The stock decreased 0.37% or $0.01 during the last trading session, reaching $2.68. About 165,153 shares traded. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since February 19, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.

Pacific Heights Asset Management Llc decreased Nucor Corp (NUE) stake by 19.55% reported in 2017Q3 SEC filing. Pacific Heights Asset Management Llc sold 26,000 shares as Nucor Corp (NUE)’s stock declined 11.33%. The Pacific Heights Asset Management Llc holds 107,000 shares with $6.00M value, down from 133,000 last quarter. Nucor Corp now has $21.79 billion valuation. The stock increased 4.51% or $2.96 during the last trading session, reaching $68.54. About 5.31 million shares traded or 69.61% up from the average. Nucor Corporation (NYSE:NUE) has risen 21.74% since February 19, 2017 and is uptrending. It has outperformed by 5.04% the S&P500.

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. The firm has “Neutral” rating by Roth Capital given on Friday, November 20. The rating was downgraded by TH Capital on Friday, November 20 to “Neutral”. The firm has “Buy” rating given on Monday, June 13 by Roth Capital. The firm has “Buy” rating given on Thursday, September 7 by H.C. Wainwright. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Hold” rating given on Thursday, June 8 by H.C. Wainwright. The rating was upgraded by Zacks on Friday, August 7 to “Hold”. H.C. Wainwright maintained Aptose Biosciences Inc. (NASDAQ:APTO) rating on Wednesday, December 13. H.C. Wainwright has “Buy” rating and $6.0 target. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, November 11. The firm has “Buy” rating given on Monday, October 30 by H.C. Wainwright.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $69.70 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Among 19 analysts covering Nucor Corporation (NYSE:NUE), 12 have Buy rating, 0 Sell and 7 Hold. Therefore 63% are positive. Nucor Corporation had 80 analyst reports since July 22, 2015 according to SRatingsIntel. Morgan Stanley downgraded Nucor Corporation (NYSE:NUE) on Tuesday, September 12 to “Equal-Weight” rating. The firm has “Buy” rating by Deutsche Bank given on Wednesday, July 6. As per Wednesday, May 24, the company rating was upgraded by Credit Suisse. As per Wednesday, October 14, the company rating was initiated by Berenberg. Morgan Stanley maintained Nucor Corporation (NYSE:NUE) on Tuesday, February 6 with “Equal-Weight” rating. On Tuesday, November 29 the stock rating was downgraded by Macquarie Research to “Underperform”. The firm has “Hold” rating given on Monday, April 24 by BMO Capital Markets. The firm has “Hold” rating given on Thursday, July 20 by Cowen & Co. Argus Research maintained the shares of NUE in report on Monday, December 12 with “Buy” rating. Jefferies maintained the shares of NUE in report on Wednesday, September 16 with “Buy” rating.

Since September 19, 2017, it had 0 insider buys, and 4 insider sales for $2.51 million activity. The insider Utermark D. Chad sold 9,003 shares worth $537,659. On Monday, October 23 the insider FERRIOLA JOHN J sold $913,959. Shares for $137,912 were sold by HAYNES VICTORIA F on Tuesday, September 19.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: